DON in Pediatric Cerebral Malaria
Key facts
- Who runs it
- Douglas Postels, MD, MS
- Where
- Malawi2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 152 people, planned
- Started
- 16 Aug 2022
- Expected to end
- 30 Nov 2028
- Type of study
- Interventional, 13 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- 6-diazo-5-oxo-L-norleucine (DON)
- Placebo
- Record updated
- 23 October 2026
Who can take part
- Age
- 12 months to 14 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 41 criteriaShow less
Who can take part
- For Healthy Adults (Part 1):
- 18 years and older
- Informed consent obtained and ICF signed
- Temperature ≤ 37.5 °C
- BMI 18.5-25 kg/m2
- Creatinine ≤ 110 mmol/L (≤ 1.2 mg/dL; males) or ≤ 90 mmol/L (≤ 1.0 mg/dL; females)
- Hemoglobin ≥ 7 g/dL or hematocrit/ packed-cell volume (PCV) ≥ 20%
- Thick or thin blood smear negative for asexual forms of P. falciparum
- Negative pregnancy test for persons of child-bearing potential; For Adults with Uncomplicated Malaria (Part 1):
- 18 years and older
- Informed consent obtained and ICF signed
- Temperature ≥ 38 °C or history of fever in the past 24 hours
- Thick or thin blood smear positive for asexual forms of P. falciparum (parasite count and speciation documented)
- Hemoglobin ≥ 7 g/dL or hematocrit/ PCV ≥ 20%
- BMI 18.5-25 kg/m2
- Creatinine ≤ 110 mmol/L (≤ 1.2 mg/dL; males) or ≤ 90 mmol/L (≤ 1.0 mg/dL; females)
- Glasgow coma score of 15
- Respiratory rate ≤ 20 breaths/ minute
- Oxygen saturation ≥ 90% on room air
- Negative pregnancy test for person of child-bearing potential; For Children with Cerebral Malaria (Part 2):
- Age 12 months-14 years old
- Informed consent obtained and ICF signed by parent or guardian
- Temperature ≥ 38 °C or history of fever in the last 24 hours
- Thick or thin blood smear positive for asexual forms of P. falciparum
- Blantyre coma score ≤ 2
- No other explanation for coma by history or physical exam
- Hematocrit or PCV ≥ 18%
- Negative pregnancy test for persons of child-bearing potential
- Creatinine ≤ 1.5 mg/dL
- Aspartate aminotransferase (AST) < 280 IU/L
- Alanine aminotransferase (ALT) < 195 IU/L
Who cannot take part
- Pregnancy or lactation (participants of child-bearing potential ages 9-59 years will undergo pregnancy testing prior to administration of the intervention)
- Currently taking highly active antiretroviral therapy (HAART)
- Currently taking anti-tuberculosis medications
- Have taken a CYP3A4 inhibitor within 7 days of enrollment
- Allergy to ondansetron or ceftriaxone; Additional Exclusion Criteria for Children with Cerebral Malaria (Part 2):
- Cloudy cerebrospinal fluid (indicative of a probable bacterial central nervous system infection)
- Allergy to ondansetron or ceftriaxone
- Participants attempting to become pregnant
- Severe malnutrition (>3 standard deviations below the mean weight for height and/ or mid-upper arm circumference (MUAC) ≤11.5 cm
- Coma for > 72 hours
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the safety of a single intravenous dose of DON in healthy adults, adults with uncomplicated malaria, and children 12 months-14 years old with clinically defined Cerebral Malaria. The main objectives are:
Read full original descriptionShow less
* Evaluate the safety of a single intravenous dose of DON in healthy adults and adults with uncomplicated malaria ( Part 1) * Determine the safety of a single dose of DON in children 12 months-14 years old with World Health Organization (WHO) clinically defined CM (Part 2 :Cohort 1-4) * Determine the pharmacokinetic (PK) profile of a single dose of DON in healthy adults, adults with uncomplicated malaria and children with CM (Part 1, and Cohorts 1-4 of Part 2) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with CM is associated with improved intracerebral blood flow dynamics on transcranial doppler (TCD) (Part 2 :Cohort 1-4) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with CM is associated with a reduction in brain volume score on magnetic resonance imaging (MRI) (Part 2 :Cohort 1-4) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with cerebral malaria is associated with changes in electroencephalogram (EEG) pattern (Part 2 :Cohort 1-4) * Exploratory: Explore the metabolic mechanisms of action of adjunctive DON in children with CM
Healthy adult participants will receive:
* anti-emetic ondansetron * one dose of DON
Adults with uncomplicated malaria will receive:
* anti-emetic ondansetron * one dose of DON * artemisinin-combination therapies per Malawi Ministry of Health guidelines
Pediatric participants will receive:
* one dose of DON * anti-emetic ondansetron and per Malawi Ministry of Health guidelines: * enteral lumefantrine-artemether therapy, and * artesunate therapy
The 13 groups in the trial
- Dose escalation in healthy Malawian adults - 0.1 mg/kg IV DONTreatment being tested
The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
Treatment: 6-diazo-5-oxo-L-norleucine (DON)
- Dose escalation in healthy Malawian adults - 1.0 mg/kg IV DONTreatment being tested
The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
Treatment: 6-diazo-5-oxo-L-norleucine (DON)
- Dose escalation in healthy Malawian adults - 5.0 mg/kg IV DONTreatment being tested
The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
Treatment: 6-diazo-5-oxo-L-norleucine (DON)
- Dose escalation in healthy Malawian adults - 10.0 mg/kg IV DONTreatment being tested
The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.
Treatment: 6-diazo-5-oxo-L-norleucine (DON)
- Dose escalation in Malawian adults with uncomplicated malaria - 0.1 mg/kg IV DONTreatment being tested
The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
Treatment: 6-diazo-5-oxo-L-norleucine (DON)
- Dose escalation in Malawian adults with uncomplicated malaria - 1.0 mg/kg IV DONTreatment being tested
The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
Treatment: 6-diazo-5-oxo-L-norleucine (DON)
- Dose escalation in Malawian adults with uncomplicated malaria - 5.0 mg/kg IV DONTreatment being tested
The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
Treatment: 6-diazo-5-oxo-L-norleucine (DON)
- Dose escalation in Malawian adults with uncomplicated malaria - 10.0 mg/kg IV DONTreatment being tested
The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.
Treatment: 6-diazo-5-oxo-L-norleucine (DON)
- Dose escalation in Malawian children with cerebral malaria - 0.1 mg/kg IV DON - Cohort 1Treatment being tested
After adult doses are shown to be safe. Of the first 6 children with cerebral malaria enrolled, 4 will receive 0.1 mg/kg IV DON, and 2 will receive placebo.
Treatment: 6-diazo-5-oxo-L-norleucine (DON)
- Dose escalation in Malawian children with cerebral malaria - 0.1 mg/kg IV DON - Cohort 2Treatment being tested
10 participants will receive 0.1 mg/kg IV DON, and 2 will receive placebo.
Treatment: 6-diazo-5-oxo-L-norleucine (DON)
- Dose escalation in Malawian children with cerebral malaria - 1.0 mg/kg IV DON - Cohort 3Treatment being tested
14 participants will receive 1.0 mg/kg IV DON, and 4 will receive placebo.
Treatment: 6-diazo-5-oxo-L-norleucine (DON)
- Dose escalation in Malawian children with cerebral malaria - 0.1 or 1.0 mg/kg IV DON - Cohort 4Treatment being tested
36 participants will receive 0.1 mg/kg IV DON (n=12) or 1.0 mg/kg IV DON (n=12), and 12 will receive placebo.
Treatment: 6-diazo-5-oxo-L-norleucine (DON)
- Dose escalation in Malawian children with cerebral malaria - placeboPlacebo, for comparison
Cohort 1 will dose 2 participants to receive placebo Cohort 2 will dose 2 participants to receive placebo Cohort 3 will dose 4 participants to receive placebo Cohort 4 will dose 12 participants to receive placebo
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- DON in Pediatric Cerebral Malaria: A Phase I/IIa Dose-Escalation Safety Study
- Publications
- Safety, Tolerability, and Pharmacokinetics of 6-Diazo-5-Oxo-L-Norleucine in Malawian Adults With and Without Malaria: A Phase 1 Dose-Escalation Clinical Trial.The Journal of infectious diseases, 2026
- DON in pediatric cerebral malaria, a phase I/IIA dose-escalation safety study: study protocol for a clinical trial.Trials, 2024
- Record updated
- 23 October 2026